Surrey Heartlands

Joint Formulary & PAD

Tranexamic acid - Fibrinolysis

You are here : Home > Formulary Search > Tranexamic acid - Fibrinolysis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
 

Status 2

Red
Formulations :
  • Injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
 

Status 3

Non Formulary
Formulations :
  • Capsules
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD1
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Tranexamic acid
Indication :
Fibrinolysis
Group Name :
Keywords :
menorrhagia, heavy mentrual bleeding, hereditary angioedema, epistaxis, nose bleeds
Brand Names Include :
Cyklokapron
Important Information :
Includes menorrhagia, epistaxis and local fibrinolysis
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
3

Other Indications

Below are listed other indications that Tranexamic acid is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Fibrinolysis.

  • No records returned.

Committee Recommendations (1)

03 May 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Tranexamic acid has been considered by the PCN and has been assigned a GREEN traffic light status, within its LICENSED indication(s).

NOTE - the branded product (Cyklokapron) was considered BLACK at the PCN in May 2017.